Company news

Xbrane Biopharma AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xbrane Biopharma releases Interim Report for January-June 2026

July 17, 2026

Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex® (Daratumumab)

June 11, 2026

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)

June 3, 2026

Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities

May 5, 2026

XBRANE submits ranibizumab biosimilar candidate to FDA

April 30, 2026

Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States

March 31, 2026

Xbrane has released the company's 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.

March 31, 2026

Xbrane Biopharma releases Year-end Report 2025

February 20, 2026

Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution

November 24, 2025

XBRANE updates on timing for resubmission of the BLA for its ranibizumab biosimilar candidate to FDA

November 19, 2025

Xbrane Enters Into Conditional Financing Deal Related To Ranibizumab Biosimilar

October 27, 2025

Xbrane Biopharma releases Interim Report for January-September 2025

October 24, 2025

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.